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Abstract
Background: There is evidence of statin benefit among patients with diabetes regardless of cholesterol levels or
prior cardiovascular disease history. Despite the evidence, there is under-prescription of statins in clinical practice.
This study aimed to assess statin prescriptions and associated factors among patients with type 2 diabetes in
Botswana.
Methods: The study was a secondary data analysis of 500 randomly selected type 2 diabetes patients at a
specialised diabetes clinic at Gaborone, Botswana. We assessed the proportion of statin-eligible patients who are
prescribed statins and evaluated the adjusted associations between various factors and statin prescriptions.
Results: Overall, 477 (95.4%) participants were eligible for a statin prescription. Clinicians prescribed statins in 217
(45.5%) of eligible participants, and only one (4.4%) ineligible participant. The probability of a statin prescription was
higher in participants with high baseline low-density lipoprotein cholesterol (risk ratio [RR]: 1.49; 95%CI: 1.17–1.89),
increasing duration of diabetes (RR: 1.01; 95%CI 1.00–1.03) and the presence of chronic kidney disease (RR: 1.35;
95%CI: 1.06–1.74).
Conclusion: A large proportion with type 2 diabetes in Gaborone is not receiving statins. Clinicians did not
consider most guideline-recommended indications for statin prescriptions. The findings call for improvement in
diabetes quality of care by implementing evidence-based guideline recommendations.
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Background
Cardiovascular disease (CVD), which includes coronary
artery disease (CAD), cerebrovascular accident (CVA),
and peripheral arterial disease (PAD), is common and
contributes to over two-thirds of mortality among pa-
tients with type 2 diabetes mellitus [1–3]. While the
presence of type 2 diabetes alone confers the highest risk
for CVD of any single risk factor, the coexistence of
other cardiovascular risk factors is a common
phenomenon [3, 4]. Consequently, guidelines advise
screening and optimal treatment of CVD risk factors in
patients with diabetes [5, 6]. Besides, prescribing of 3-
hydroxy-3-methylglutaryl-coenzyme A reductase inhibi-
tors (statins) among patients with type 2 diabetes re-
duces the risk of major CVD events by 23–33% [7–9].
There is evidence of statin benefit among patients with
diabetes regardless of their low-density lipoprotein chol-
esterol (LDL-C) values or prior CVD history [7, 9–14].
For each mmol/l reduction in LDL-C, there is evidence
of a 9% relative reduction in all-cause mortality in
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patients with diabetes [15]. Irrespective of LDL-C, guide-
lines recommend statins for patients with diabetes aged
≥40 years without atherosclerotic cardiovascular disease
(ASCVD), or those who are younger than 40 years but
with existing ASCVD or additional risk factors [5, 6].
While some studies in developed countries have re-
ported high use of statins among patients with type 2
diabetes, there has generally been under-prescribing of
statins across many countries [16–18]. Statin prescribing
among patients with type 2 diabetes is as high as 100%
in developed countries but as low as 3–13% in Africa
[17–23]. The suboptimal utilisation of statin therapy in
Africa is due to many factors, but mainly limited access
to standard diabetes care because of the high cost of
tests and medications with typically high co-payment
levels [22]. Affordability is a critical issue in several Afri-
can countries where there is no universal healthcare,
with the cost of medicines accounting for up to 70% of
total healthcare expenditure, much of which is out-of-
pocket [24, 25]. Statin under-prescribing is a concern
given the high growth rates of cardiovascular diseases in
sub-Saharan African countries and current poor control
of cardiovascular diseases [26–31]. The underuse of sta-
tins significantly increases the incidence of cardiovascu-
lar events and associated mortality [32]. Although
healthcare is free in Botswana, factors not related to cost
may still affect the uptake of statins in patients with dia-
betes. This is problematic given current prevalence rates
of diabetes in Botswana and the resultant impact on
morbidity and mortality [33–35]. Published data on the
impact of diabetes mellitus on CVD in Botswana are
scant. About a quarter of patients admitted with heart
failure had type 2 diabetes in a recent study in Gaborone
[33]. Although data on atherosclerotic diseases in
Botswana are missing, we can expect that diabetes-
related coronary atherosclerosis underlines some cases
of heart failure [33, 35]. In addition, the rising burden
and suboptimal control of CVD risk factors in patients
with type 2 diabetes have become an increasing concern
in Botswana [36]. One of the critical steps that will pre-
vent or slow ASCVD in this suboptimally-treated pa-
tients is the use of statins [5]. Currently, there is no
study assessing the extent of statin prescriptions among
patients with type 2 diabetes in Botswana. We aimed to
address this by evaluating the extent of statin prescrip-
tion among patients with type 2 diabetes in Botswana.
Our secondary aim was to determine factors associated
with statin prescription among type 2 diabetes.
Methods
Study design
We conducted a secondary analysis of data from a previ-
ous study among type 2 diabetics at a specialised dia-
betes clinic in Gaborone, Botswana. Any concerns with
the management of diabetic patients in this dedicated
clinic are likely to be exacerbated in non-specialist cen-
tres such as primary healthcare centres.
Participant recruitment and data collection
The original study took place between August 2017 and
February 2018 [36]. The primary objective of the original
study was to assess glycaemic, low-density lipoprotein,
and hypertension control in patients with type 2 dia-
betes. The study included 500 randomly selected pa-
tients with type 2 diabetes aged ≥18 years, attending the
clinic for at least 3 months before data collection. Using
systematic random sampling, we enrolled every eighth
patient from the daily lists of patients attending the
clinic. The enrolment occurred in the mornings and af-
ternoons until either the daily target of ten patients was
achieved or the end of clinic consultations. Demographic
data (age, sex, occupation, educational attainment, and
marital status), duration of diabetes, and the type of dia-
betes medications were collected. Other information was
the history of hypertension, lipid disorders, ischemic
heart diseases, stroke or peripheral vascular disease. We
also recorded data on the use of medications for hyper-
tension and lipid disorders (including statins), and an-
thropometric measurements (weight, height, hip and
waist circumferences). With participants in light clothing
and without footwear, we measured participants’ height
and weight to the nearest 0.1 cm (cm) and 0.1 kg (kg) re-
spectively [37]. We also measured the hip and waist cir-
cumferences (to the nearest 0.1 cm a non-stretchable
tape measure at a hip and level midway between the
lowest rib and iliac crest [38]. After 10 min of rest, three
seated blood pressure (BP) measurements were taken
from the right arm using a digital automatic BP monitor
(Omron) [37, 39]. We documented the average of the
three readings and that of each patient’s previous visit.
In addition, we used the electronic medical records to
obtain participants’ serum creatinine and low-density
lipoprotein-cholesterol (LDL-C), and urine dipsticks for
proteinuria results within 6 months of enrolment [36].
The diabetes clinic has a satellite laboratory that per-
forms tests per protocol as defined by the ISO-9000 cer-
tified Princess Marina Hospital clinical laboratory. Total
cholesterol (TC), triglycerides (TG) and high-density
lipoprotein cholesterol (HDL-C) are measured enzymati-
cally in plasma using commercial kits made by Roche
Diagnostics, Switzerland. LDL-cholesterol was calculated
using the Friedwald formula as TC-HDL-C-TG/2.2 in
mmol/dL [40]. For the present study, we evaluated the
extent of statin prescriptions among the participants.
The primary outcome measure was receiving a statin
prescription among statin-eligible participants. We
assessed statin eligibility based on the Society for Endo-
crinology, Metabolism, and Diabetes of South Africa
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(SEMDSA) guidelines [6]. According to SEMDSA, the
eligibility for statin prescribing included any CVD or
chronic kidney disease (CKD), age above 40 years, and
diabetes duration longer than ten years. In addition, a
statin prescription is indicated in the presence of one or
more of the following cardiovascular risk factors; hyper-
tension, cigarette smoker, HDL-C level, family history of
early CAD, and any albuminuria [6]. Other independent
variables included baseline serum LDL-C, body mass
index (BMI), waist-hip ratio (WHR) and level of
education.
Definition of terms
The diagnosis of hypertension based on the self-reported
history of hypertension, the use of hypertension-
lowering medications or sustained blood pressure ≥ 140/
90 mmHg in more than one visit [41]. We defined CVD
as the history of CAD, CVA (ischemic stroke, transient
ischemic attacks), or PAD [6]. CAD was any docu-
mented definite or probable myocardial infarction,
CAD-related revascularisation (surgery, angioplasty,
stenting, or any combination of these), or stable angina
in participants’ medical records [42]. Data on CVA and
PDA were extracted from participants’ medical records
as defined by the treating physician. Smoking status was
a documented self-report of current smoking habits. We
estimated glomerular filtration rate (eGFR) using the
Modification of Diet in Renal Disease(MDRD), and clas-
sified patients with eGFR < 60ml/minute/1.73m2 as hav-
ing CKD [43]. BMI was categorized into underweight for
BMI < 18.5 kg/m2; normal for BMI of 18.5–24.9 kg/m2,
overweight for 25.0–29.9 kg/m2; or obese for BMI ≥30
kg/m2 [44]. We also calculated the WHR by dividing
waist circumference (cm) by hip circumference (cm) and
defined WHR ≥ 0.85 for women and ≥ 0.90 for men as
high [38]. Dipstick proteinuria appeared as negative (−),
trace, (+), (++), or (+++) in the dataset. We classified
proteinuria in individuals with ≥ (+) dipstick proteinuria
results. For patients already on lipid-lowering medica-
tions and whose baseline ‘untreated’ levels of lipid profile
were not available, we estimated the LDL-C levels before
the initiation of statin treatment as in previous studies
[45]. The adjustment was made based on the assumption
that most patients received atorvastatin (the only statin
available in the public sector in Botswana) at a dosage of
at least 10 mg per day and an overall adherence of 60%
[46]. We calculated the baseline LDL-C levels by assum-
ing that the measured LDL-C is a result of a 25% reduc-
tion from baseline [45]. Baseline LDL-C levels above
4.13 mmol/l were considered high [47].
Statistical analysis
Clean data were imported from MS Excel and analysed
using Stata Version 14 (Stata Corp, College Station, TX).
Categorical variables were presented as frequencies and
percentages, and continuous variables as mean (standard
deviation [SD]) or medians [first–third quartiles]. Com-
parison of clinical and demographic factors by gender and
statin use was achieved by using the Chi-square or Fisher’s
exact tests for categorical variables, and independent stu-
dent’s t-tests or Wilcoxon rank-sum test for continuous
variables as appropriate. A 2-sided p-value < 0.05 was con-
sidered as statistically significant. As the outcome of inter-
est (a statin prescription) was a common event, and our
study design was cross-sectional, we estimated relative
risks (RRs) as measures of association. Log-binomial
models or generalised linear models for the binomial fam-
ily were fitted to assess for independent predictors for sta-
tin prescribing. The multivariable model included all
factors with p < 0.2 on bivariate analysis. We used a back-
ward selection modelling method with probabilities set at
0.05 and 0.1 for inclusion and exclusion; respectively. We
report adjusted risk ratios (RRs), 95% confidence intervals
(CIs), and p-values. With a sample size of 477 statin-
eligible participants, we were able to estimate the preva-
lence of statin use of 13% with a margin of error of 3% on
a two-sided alpha level of 0.05 [22].
Results
There were 500 participants in the dataset, with a mean
(SD) age of 58.9 (12.2) years and 330 (66%) were fe-
males. Table 1 summarises baseline participants’ charac-
teristics by gender. The majority (96.7%) of participants
aged ≥40 years and women were significantly older than
men. Approximately a third (34.4%) of participants had
a diabetes duration of over ten years. Hypertension
(84.7%) and obesity (51.6%) were prevalent, especially in
female participants. Overall, CKD (11.3%), proteinuria
(10.7%), CVD (8.8%), and smoking (3.4%) were uncom-
mon. The mean (SD) baseline LDL-C was 3.1 (1.2)
mmol/L, and significantly higher in female than male
participants.
Statin eligibility and prescribing rates
Of the 500 participants, 477 (95.4%) were eligible for a
statin prescription. Clinicians prescribed statins (exclu-
sively atorvastatin) in 217 (45.5%) of statin-eligible par-
ticipants, and only one (4.4%) ineligible participant.
Seven (1.5%) participants received prescriptions of other
lipid-lowering medications alone or in combination with
statins. Of those who were eligible for statins, statin-
prescribed individuals differed from those without pre-
scriptions in several parameters on the bivariate analysis
(Table 2). Relative to the statin-non-prescribed group,
the statin-prescribed group had a longer duration of dia-
betes (8.9 years vs. 6.0 years; p < 0.001); were older (61.5
years vs 59.2 years; p = 0.018), more likely to be hyper-
tensive (85.7% vs 78.1%; p < 0.032), more likely to have
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CKD (17.2% vs 6.6%; p = 0.001), and a higher baseline
LDL-C (3.3 vs 2.9 mmol/L; p < 0.001). The two groups
did not differ significantly in the presence of CVD, pro-
teinuria and gender.
Multivariable analysis
The multivariable log-binomial model examined ad-
justed associations between statin prescription and vari-
ous factors. The best fit had the following covariates:
age, the duration of diabetes, BMI, hypertension, a high
baseline LDL-C, CKD, CVD, and proteinuria. Increasing
diabetes duration was associated with an increased likeli-
hood (RR: 1.01; 95%CI 1.00–1.03) of receiving a statin
prescription (Table 3). The presence of CKD (RR: 1.35;
95%CI: 1.06–1.74) and a high baseline LDL-C (RR: 1.49;
95%CI: 1.17–1.89) were also associated with an increased
likelihood of a statin prescription. Age, BMI, history of
CVD, and a diagnosis of hypertension were not
Table 1 Demographic and clinical characteristics of patients with type 2 diabetes at a specialised Diabetes clinic in Gaborone (N = 477)
Characteristics All (N = 477) Males (n = 160) Females (n = 317)
Age, mean(SD), years 60.3(10.8) 56.8(11.5) 62.0(10.1)
Age > 40 years n(%) 461(96.7) 150(93.8) 311(98.1)
Diabetes duration, median, IQR, years 7(3–13) 8.9(3–14) 7 (3–13)
Diabetes duration > 10 years n(%) 164 (34.4) 63(39.4) 101(31.9)
BMI, mean (SD) kg/m2 30.7(6.0) 29.0(5.2) 31.6(6.1)
Normal weight n(%) 85(17.8) 39(24.4) 46(14.5)
Overweight n(%) 146(30.6) 59(36.7) 87(27.4)
Obese n(%) 246(51.6) 62(38.8) 184(58.0)
Marital status
Living alone n(%) 247(51.8) 47(29.4) 200(63.1)
Living with a partner n(%) 230(48.2) 113(70.6) 117(36.9)
Education status
≤ Primary education, n(%) 306(64.1) 82(51.3) 224(70.7)
≥ Secondary or tertiary, n(%) 171(35.9) 78(48.7) 93(29.3)
WHR, mean (SD) 0.94(0.10) 0.97(0.08) 0.93(0.09)
Low WHR n (%) 79(16.6) 67(41.9) 12(3.8)
High WHR n (%) 398(83.4) 93(58.1) 305(96.2)
Hypertension n (%) 404(84.7) 120(75.0) 284(89.6)
Use of antihypertensive n (%) 389(81.6) 110(68.8) 279(88.0)
Smoking n (%) 16(3.4) 12(7.5) 4(1.3)
Lipid-lowering medications n (%) 224(47.0) 70(43.8) 154(48.6)
Statins n (%) 217(45.5) 68(42.5) 149(47.0)
Others n (%) 7(1.5) 2(1.6) 5(1.6)
CVD n (%) 42(8.8) 15(9.4) 27(8.5)
PAD n (%) 11(2.3) 3(1.9) 8(2.5)
Coronary artery disease n (%) 12(2.5) 5(3.3) 7(2.2)
Cerebrovascular disease n (%) 22(4.6) 8(5.0) 14(4.4)
CKD n (%) 54(11.3) 24(15.0) 30(9.5)
Proteinuria n (%) 51(10.7) 27(16.9) 24(7.6)
HbA1c mean (SD), % 8.4(2.4) 8.5(2.6) 8.3(2.3)
Baseline LDL-C, mean (SD), mmol/L 3.1(1.2) 2.8(1.1) 3.3(1.2)
Normal 315(66.0) 113(70.6) 202(63.7)
High 59(12.4) 9(5.6) 50(15.8)
Missing 103(21.6) 38(23.8) 65(20.5)
Legend: BMI Body Mass Index, CKD chronic kidney disease, CVD cardiovascular disease, HbA1c Haemoglobin A1c, IQR interquartile range, LDL-C low-density
lipoprotein cholesterol, PAD peripheral artery disease, SD standard deviation, WHR waist-hip ratio
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associated with statin prescribing after adjustment for
the other variables in the model.
Discussion
Less than half of the statin-eligible patients with type 2
diabetes at a specialised diabetes clinic in Botswana
received a statin prescription. A longer duration of dia-
betes, a higher baseline LDL-C and the presence of
chronic kidney disease were independently associated
with the tendency to prescribe statins.
The under-prescription of statins in this population is
a concern since the use of statins appreciably reduces
Table 2 Factors associated with statin prescription among statin-eligible patients with type 2 diabetes at a specialised Diabetes
clinic in Gaborone (N = 477)
Characteristics Statin not prescribed (n = 260) Statin prescribed (n = 217) P-value
Sex
Males, n (%) 92(35.4) 68(31.3) 0.351
Female, n (%) 168(64.6) 149(68.7)
Diabetes duration, median, IQR, years 6(2–12) 8.9(4–15) < 0.001
Duration ≤10 years 179(68.9) 134(61.8) 0.104
Diabetes duration > 10 years 81(31.1) 83(38.2)
Age, mean (SD), years 59.2(10.8) 61.5(10.7) 0.018
Age≤ 40 years, n (%) 12(4.6) 4(1.8) < 0.094
Age > 40 years n (%) 248(95.4) 213(98.2)
Marital status
Living alone n (%) 135(51.9) 112(51.6) 0.946
Living with a partner n (%) 125(48.1) 105 (48.4)
Education status
≤ Primary education, n (%) 166(63.9) 140(64.2) 0.879
≥ Secondary or tertiary, n (%) 94(36.1) 77(35.8)
Hypertension n (%) 212(81.5) 192 (88.5) 0.036
Antihypertensive use n (%) 203(78.1) 186(85.7) 0.032
Smoking 13(5.0) 3(1.4) 0.029
CVD, n (%) 20(7.7) 22(10.1) 0.538
PAD, n (%) 7(2.7) 4(1.8) 0.625
Coronary artery disease n (%) 6(2.3) 6(2.8) 0.751
Cerebrovascular diseases n (%) 9(3.5) 13(6.0) 0.190
BMI, mean (SD) kg/m2 30.3(5.7) 31.2(6.2) 0.113
Normal weight n (%) 50(19.2) 35(16.1) 0.669
Overweight n (%) 79(30.4) 67(30.9)
Obese n (%) 135(47.9) 115(52.8)
WHR, mean (SD) 0.94(0.08) 0.95(0.10) 0.106
Low WHR n (%) 46(17.7) 33(15.2) 0.467
High WHR n (%) 214(82.3) 184(84.8)
CKD, n (%) 20(7.7) 34 (15.7) 0.006
Proteinuria, n (%) 30 (11.5) 21(9.7) 0.512
HbA1c mean (SD), % 8.4(2.6) 8.4(2.2) 0.948
Baseline LDL-C mean (SD), mmol/L 2.9(0.9) 3.3(1.4) 0.003
Normal 177(68.1) 120(55.3) < 0.001
High 17(6.5) 42(19.4)
Missing 66(25.4) 55(25.3)
Legend: BMI body mass index, CKD chronic kidney disease, CVD cardiovascular disease, HbA1c haemoglobin A1c, IQR interquartile range, LDL-C low-density
lipoprotein cholesterol, PAD peripheral artery disease, SD standard deviation, WHR waist-hip ratio
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cardiovascular morbidity and mortality in patients with
diabetes irrespective of their LDL-C levels [7, 9–13].
Whilst the proportion of patients with diabetes who are
prescribed statins varies substantially worldwide; there is
a low prescribing of statins both in developing and de-
veloped countries [18, 19, 21–23, 48–51]. Encouragingly,
the percentage of patients with diabetes who received
statins (45.5%) in our study appears appreciably higher
than the 3–13% seen in some African countries and con-
sistent with findings from developed countries where be-
tween 25 to 73% of patients with diabetes are prescribed
statins [18, 19, 22, 48–50]. The proportion of statin pre-
scription in this population is higher than has been re-
ported in some developed countries, including Germany
(25%) and the United Kingdom (33%) [18, 48]. While
the finding of a comparatively higher statin prescription
in this setting than some African countries and some de-
veloped countries is encouraging, there is no reason for
complacency as more than half of our patients were
without CVD protection by statins. Similar to developed
countries, one potential explanation for low statin pre-
scribing rates among our patients with diabetes is inad-
equate adherence to guidelines [22, 51–53]. Whereas
there may be a fear of the association of statin therapy
with a slightly increased risk of developing diabetes, the
benefits of statins in reducing cardiovascular morbidity
and mortality among patients with established diabetes
should dispel these concerns [7–9, 54]. As mentioned,
several epidemiological studies have observed a lower
proportion of statin prescribing in patients with diabetes
in Africa than in this population [21–23]. In addition to
inadequate adherence to guidelines, the main reasons for
low statin prescribing in Africa include limited access to
these medicines due to their high cost with high co-
payment levels, inaccessibility to lipid testing facilities
and unavailability of guidelines [22]. The presence of
free consultations, tests and medications in Botswana
might explain our higher statin prescribing rates than
those seen in other African settings without universal
health access. Irrespective of the reasons, it is imperative
that statins are routinely prescribed to reduce the risk of
CVD events in patients with type 2 diabetes [7–13, 15,
55].
Our results of increasing statin prescribing with in-
creasing diabetes duration also agree with previous re-
search findings [56]. This finding is reassuring as a
longer duration of diabetes leads to an increased risk of
CVD. For this reason, guidelines recommend statins for
patients with diabetes for more than ten years [5, 6]. Al-
though the median diabetes duration was seven years in
our participants, the association between statin prescrib-
ing and diabetes duration was still apparent. The finding
may suggest that clinicians correctly recognise a longer
duration of diabetes as an indication for statin therapy.
As it may take time for the transmission of information
between clinicians and patients, the acceptance of new
medications is likely easier as the diabetes duration in-
creases [57].
Another finding in our study was that the presence of
CKD increased the likelihood of statin prescribing. This
finding is also encouraging as statins reduce mortality by
up to 36% in patients with kidney failure [5, 6, 58, 59].
The finding is also consistent with SEMDSA guideline
recommendations of a statin for every patient with dia-
betes and CKD [6]. While albuminuria is a marker of
renal disease, participants with proteinuria did not re-
ceive statin prescriptions. We can postulate that clini-
cians do not recognise proteinuria as a predictor of CVD
and an indication for statins in patients with diabetes.
This finding warrants further investigation as it is in
contrast with Berthold et al., who reported increased
odds of statin prescribing in type 2 diabetes patients
with proteinuria in Germany [18].
Our findings that a high baseline LDL-C increased the
likelihood of statin prescribing agreed with those of
Berthold at al. that showed an 11% increase in statin
prescribing rates for every 0.26 mmol/L increase in LDL-
C [18]. This finding also confirms the observation from
previous studies that prescribers tend to respond more
to the pre-treatment LDL-C value than to the patients’
overall CVD risk profile as described in clinical guide-
lines [9, 52]. Although there is a lack of local guidelines,
our diabetes clinic adopted the SEMDSA guidelines
which recommend statins along with lifestyle changes
regardless of cholesterol levels for all patients with dia-
betes aged > 40 with or without CVD [6]. Our findings
that statin prescription was based on LDL-C level may
suggest a need for deliberate efforts for improving the
understanding and implementation of the adopted
guidelines, and we will be taking this further.
In most clinical guidelines, the presence of CVD,
CKD, patients age, diabetes and presence of CVD risk
Table 3 Adjusted relative risks for associations between various
factors and statin prescription among statin eligible patients
with diabetes at a specialised diabetes clinic in Botswana
Characteristic Risk ratio 95% Conf. Interval p-value
Age, years 1.006 0.994–1.017 0.362
CKD 1.354 1.055–1.738 0.017
Hypertension 1.336 0.846–2.110 0.213
BMI, kg/m2 1.014 0.994–1.034 0.16
High baseline LDL 1.488 1.173–1.887 0.001
Diabetes duration, years 1.014 1.000–1.027 0.048
Proteinuria 0.979 0.644–1.488 0.922
CVD 0.901 0.623–1.303 0.581
Legend: BMI body mass index, CKD chronic kidney disease, CVD cardiovascular
disease, LDL-C low-density lipoprotein cholesterol
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factors such as hypertension, albuminuria and cigarette
smoking are indicators of prescribing statins among pa-
tients with type 2 diabetes [5, 6]. The presence of any of
the above factors is associated with an increased risk of
CVD. Except for CKD and duration of diabetes, none of
the other indications was a predictor of statin prescrip-
tions in this population. Given the high prevalence of
hypertension and other indications in this population,
most participants would have qualified for statins if
guideline recommendations were followed. As our clinic
has adopted the SEMDSA guidelines, this finding is a
concern and a call for efforts to improve its implementa-
tion for the benefit of this high-risk population.
We are aware of a number of limitations of our study.
We estimated the baseline LDL-C levels by a 25% adjust-
ment of measured LDL. There was a risk of either over-
estimation or underestimation of the baseline LDL-C
due to possible errors in our assumptions of the dosage
and adherence of atorvastatin. Although measured LDL-
C results were available for most of the included partici-
pants, HDL cholesterol results were mostly missing.
Guidelines consider HDL as one of the factors for statin
prescribing in patients with diabetes. However, data for
all other indications for statin prescribing were available
in dataset. We did not document the dosage of statin
used in our patients; hence, we are unable to determine
whether moderate to high-intensity statins were pre-
scribed as recommended by the guidelines. In addition,
we were unable to identify patients with contraindica-
tions to warfarin as the information was not available.
The study was also performed in one clinic, hence limit-
ing the generalizability of the study findings to other fa-
cilities in the country. However, being one of the few
specialised diabetes clinics in Botswana, our results likely
characterise the ‘finest’ diabetes care in the country.
Consequently, the highlighted concerns are likely to be
greater in non-specialist healthcare facilities treating pa-
tients with type 2 diabetes in Botswana.
Conclusion
In conclusion, we believe this study provides a useful
and reliable picture of current statin prescribing behav-
iour in Botswana despite the limitations. There is appre-
ciable under-prescribing of statins in this high-risk
population. The presence of CKD, high baseline LDL,
and an increased duration of diabetes strongly influ-
enced statin prescriptions in patients with diabetes. Cli-
nicians did not consider most guideline-recommended
indications for the prescribing of statins. By identifying
gaps in the prescription of statins to patients with dia-
betes, the study provides an opportunity for improve-
ment in the quality of care. Furthermore, the study
findings suggest a need for further studies to investigate
the reasons for statin under-prescription in our setting.
We are following this up to provide future guidance for
clinicians in Botswana treating patients with type 2 dia-
betes, with the results likely to be of interest to other
sub-Saharan African countries with high rates of type 2
diabetes.
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